erteberel erteberel erteberel (inn, usan; former developmental code name ly-500307; also known as selective estrogen receptor beta agonist-1 or serba-1) is a synthetic, nonsteroidal estrogen which acts as a selective erβ agonist and is under development by eli lilly for the treatment of schizophrenia. it is specifically under investigation for the treatment of negative symptoms and cognitive impairment associated with the condition. as of 2015, it is in phase ii clinical trials for this indication in the united states. erteberel was also under investigation for the treatment of benign prostatic hyperplasia and reached phase ii clinical studies for this use but failed to improve symptoms in men with the condition and development for this indication was discontinued. the drug has also been proposed as a potential novel treatment for glioblastoma. erteberelclinical dataother namesselective estrogen receptor beta agonist-1; serba-1; ly-500307; (3as,4r,9br)-1,2,3,3a,4,9b-hexahydro-4-(4-hydroxyphenyl)cyclopenta(c)(1)benzopyran-8-ol; (2r,3s,4r)-serbaroutes ofadministrationby mouthidentifiers iupac name (3as,4r,9br)-4-(4-hydroxyphenyl)-1,2,3,3a,4,9b-hexahydrocyclopentachromen-8-ol cas number533884-09-2pubchem cid10286159drugbankdb07933chemspider8461628unii2zul6758tzkeggd09899chemblchembl278703comptox dashboard (epa)dtxsid70201547 chemical and physical dataformulac18h18o3molar mass282.339 g·mol−13d model (jsmol)interactive image smiles c1c2(c1)c3=c(c=cc(=c3)o)o2c4=cc=c(c=c4)o inchi inchi=1s/c18h18o3/c19-12-6-4-11(5-7-12)18-15-3-1-2-14(15)16-10-13(20)8-9-17(16)21-18/h4-10,14-15,18-20h,1-3h2/t14-,15+,18+/m1/s1key:xiessjvmwnjcgz-vkjftormsa-n erteberel has 14-fold binding selectivity for the erβ over the erα (ki = 0.19 nm versus 2.68 nm, respectively). however, it shows 32-fold functional selectivity for activation of the erβ over the erα (ec50 = 0.66 nm versus 19.4 nm, respectively). it is roughly a full agonist of both the erβ and erα (emax = 101% versus 94%, respectively). although selective for the erβ, erteberel loses its selectivity at high dosages and activates the erα as well, producing effects such as suppression of gonadal testosterone production in men.